Literature DB >> 28668897

Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.

Fuminori Ishii1, Yoichiro Yoshida2, Yasushi Yamauchi1, Naoya Aisu1, Daibo Kojima1, Toshiyuki Mera1, Daisuke Kato1, Toshihiro Tanaka3, Keiko Naito4, Kosei Yasumoto4, Takashi Kamigaki4, Shigenori Goto4, Yoshihiro Hamada5, Satoshi Nimura5, Shohta Kodama6, Suguru Hasegawa1.   

Abstract

BACKGROUND/AIM: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. PATIENTS AND METHODS: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included.
RESULTS: The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases.
CONCLUSION: Hepatectomy after chemoimmunotherapy using activated αβ T-cells for CLM can be performed safely. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; XELOX; chemotherapy; hepatectomy; immunotherapy

Mesh:

Substances:

Year:  2017        PMID: 28668897     DOI: 10.21873/anticanres.11776

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?

Authors:  Jiaqiao Fan; Dong Shang; Bing Han; Jianxun Song; Hailong Chen; Jin-Ming Yang
Journal:  Theranostics       Date:  2018-11-10       Impact factor: 11.556

2.  A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer.

Authors:  Takaaki Masuda; Atsushi Nonami; Fumiaki Tanaka; Yuki Ando; Masatoshi Eto; Koshi Mimori
Journal:  Breast J       Date:  2020-12-05       Impact factor: 2.431

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.